Our Take
Revenue growth is real; margin pressure from new hospital ramp is structural, not cyclical, and will persist as long as operators prioritize bed count over unit economics.
Why it matters
Hospital operators and healthcare investors need to separate top-line momentum from profitability trends. The sector is expanding capacity faster than it can mature new units, creating a two-speed market where growth and returns are decoupling.
Do this week
Portfolio managers: flag hospitals with >15% bed additions YoY and <24% mature unit margins before earnings calls; ask specifically when new units reach breakeven, not when they were opened.
18% Revenue Growth Masks Margin Pressure from New Hospital Openings
India's listed hospitals delivered 18% year-over-year sales growth and 16% EBITDA growth in the March 2026 quarter, per Kotak Securities research. Average revenue per occupied bed (ARPOB) rose 6–14% YoY across most operators, driven by lower average length of stay (ALOS) and higher-complexity case mix. Apollo Hospitals saw 9% ARPP growth from better pricing and case mix, combined with 7% inpatient volume growth. KIMS posted 14% ARPOB growth from high-ARPOB markets like Thane and Bengaluru.
But new bed additions are eating into profitability. Except for Apollo and Narayana Hrudayalaya, all major operators expanded operational bed count by 5–21% YoY. Four newly opened hospitals—Defence Colony, Kolkata, Hyderabad, and Pune—posted combined losses of ₹414 million in Q4 FY26, versus ₹150 million in Q3. Mature unit EBITDA margin improved to 25.5% from 24.4% YoY, but operators are not translating unit-level gains into portfolio profitability.
Max Healthcare was the outlier on volume, with just 1% ARPOB growth after discontinuing high-value chemotherapy drugs for CGHS patients and absorbing GST rate cuts. Oncology fell from 26% of sales to 21%; stripping out oncology, Max's core revenue still grew 15% YoY, suggesting the decline is policy-driven rather than demand-driven.
Diagnostics fared better. DLPL and Metropolis reported 15–17% organic sales growth on 9–13% sample volume growth and a higher wellness mix. Metropolis' 23% YoY sales growth included acquisitions (Core, DAPIC, Scientific, Ambika), but cumulative EBITDA for the diagnostic segment grew 27% YoY with 175 basis points of margin expansion, signaling that B2C diagnostics pricing is recovering as online discount wars cool.
New Units Are Diluting Entire-Portfolio Returns
The hospital sector is in a classic expansion trap. Revenue per unit is improving, inpatient volumes are steady to strong, and pricing power is real. But the speed of bed addition is outpacing the speed of unit maturation. KIMS faced empanelment delays in new insurance markets, which slowed ramp-on revenue. Medanta's Noida hospital and KIMS' Thane and Bengaluru units are dragging consolidated margins despite strong underlying unit economics in legacy hospitals.
This matters because it separates operators into two tiers: those who can absorb startup losses into portfolio-level profitability (Apollo, mature players) and those who cannot (newer or smaller operators with less operating leverage). Investors are effectively buying growth in new bed capacity, not growth in earnings. Until new units reach mature margins, portfolio EBITDA will remain rangebound even as revenue climbs.
What to Watch
Operators need to disclose new-unit breakeven timelines by market, not just by hospital. Current disclosure conflates geographic expansion (healthy) with poor unit economics (a problem). Ask: which new units have reached >20% mature EBITDA margin, and which are still sub-15%?
Investors should track the ratio of new bed capacity to mature-unit margin improvement. If beds added grow faster than mature-unit margins improve, the operator is in a value-destructive cycle. The 18% revenue growth is real, but it is not yet profit growth.